BDRX — Biodexa Pharmaceuticals Plc

Earnings Call Summary for BDRX (Q2 2021)

1. Key Financial Results and Metrics:

• Revenue Growth: The company reported an increase in revenues due to collaboration partnerships related to the Q-Sphera programs.
• Cost Management: R&D expenses were approximately £2 million, and administrative costs were £1.6 million, leading to a total net loss of just over £3 million, reflecting a monthly burn rate of about £0.5 million.
• Balance Sheet Improvement: All Spanish loans have been repaid, and the cash balance at the half-year was £4.5 million, supplemented by an additional £9 million raised in July, bringing total cash to approximately £12 million, providing a runway into Q1 2023.

2. Strategic Updates and Business Highlights:

• Pipeline Progress: The company advanced its internal programs for brexpiprazole and tacrolimus into preclinical stages. MTX110 is moving into Phase II for DIPG and Phase I for GBM, with promising preclinical data.
• Q-Sphera Technology: Significant advancements in the Q-Sphera platform were reported, particularly in successfully formulating large molecules, including monoclonal antibodies, without denaturation.
• Partnerships: The company is working with partners on several programs, with proof-of-concept formulations delivered for two projects, and ongoing discussions for expanded collaborations.

3. Forward Guidance and Outlook:

• The company expects to initiate a Phase I trial for GBM in the coming months and is refining protocols for the Phase II study for DIPG based on FDA feedback.
• The cash runway is projected to last until Q1 2023, assuming no significant licensing fees from third parties.

4. Bad News, Challenges, or Points of Concern:

• Market Response: There was disappointment regarding the lack of interest in the DIPG data, despite promising survival results, likely due to the small market size.
• Partnership Issues: The termination of the partnership with Dr. Reddy was noted as disappointing, attributed to the unsuitability of their molecules for Q-Sphera.
• Technical Challenges: Ongoing technical hurdles include developing a dissolution assay for the Q-Sphera microspheres and ensuring injectability of the product.

5. Notable Q&A Insights:

• Technical Challenges: Stephen Stamp highlighted overcoming the challenge of encapsulating proteins without denaturation and increasing drug loading threefold, but acknowledged ongoing work on dissolution assays.
• Market Strategy: The company aims to balance internal programs with partnered projects to maintain flexibility and leverage competitive pricing for licensing.
• Shareholder Engagement: Efforts to engage with investors include roadshows and research publications, although these have not yet positively impacted the share price.

Overall, while BDRX has made significant strides in its pipeline and technology, challenges remain in market perception and partnership dynamics, with a cautious but optimistic outlook for the future.